Skip to main content
Premium Trial:

Request an Annual Quote

Biotec Pharmacon, ArcticZymes, Affymetrix Reach New Deal for Shrimp Alkaline Phosphatase

NEW YORK (GenomeWeb News) – Biotec Pharmacon today announced it has reached a new non-exclusive deal with Affymetrix for the distribution of ArcticZymes' shrimp alkaline phosphatase (SAP).

ArcticZymes is a subsidiary of Biotec Pharmacon. Affy previously had the exclusive distribution rights to SAP. The new agreement provides Affy with a long-term supply of SAP at "competitive prices" and non-exclusive rights to market, distribute, and sell the product by itself or in combination with other products for life science and diagnostic applications, Biotec said.

The new deal took effect on Sept. 23, and runs through December 2017. Financial and other terms of the agreement were not disclosed.

According to Jan Buch Anderson, managing director of Norway-based ArcticZymes, SAP remains the firm's best-selling product and provides the majority of its sales.

"We are currently building our organization and increasing our sales and marketing capabilities, and it has been very important for us to gain control over the commercial development of our SAP enzyme," he said. "Hopefully this will increase our sales and also make our revenue and earnings less volatile."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.